Effects of evolving lipid-lowering drugs on carbohydrate metabolism

被引：2

作者：

Tsimihodimos, V. ^{[1
]}

Elisaf, M. ^{[1
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, Niarchou Ave, GR-45110 Ioannina, Greece

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2018年 / 137卷

关键词：

Antisense oligonucleotides; PCSK9; inhibitors; Apolipoprotein CIII inhibitors; CETP inhibitors; Lp(a); LOW-DENSITY-LIPOPROTEIN; OF-FUNCTION MUTATIONS; ALPHA/DELTA AGONIST GFT505; APOLIPOPROTEIN C-III; TARGETING APOLIPOPROTEIN(A); GLUCOSE-HOMEOSTASIS; INSULIN SENSITIVITY; DOUBLE-BLIND; BETA-CELLS; HIGH-RISK;

D O I：

10.1016/j.diabres.2017.12.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to the development of many novel lipid-lowering drugs. Accumulating evidence suggests that the interplay between carbohydrate and lipid metabolism is bidirectional. Thus, any intervention that affects lipid metabolism has the potential to influence the homeostasis of glucose. In this review we summarize the available data on the effects of the evolving lipid-lowering drugs on carbohydrate metabolism. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：1 / 9

页数：9

共 50 条

[21] Unresolved issues in lipid-lowering treatment
Tziomalos, Konstantinos
PANMINERVA MEDICA, 2016, 58 (02) : 191 - 195
[22] New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, Kyuho
Ginsberg, Henry N.
Choi, Sung Hee
DIABETES & METABOLISM JOURNAL, 2022, 46 (04) : 517 - 532
[23] Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat
Jassim, Goran
Skrede, Silje
Jesus Vazquez, Maria
Wergedal, Hege
Vik-Mo, Audun O.
Lunder, Niclas
Dieguez, Carlos
Vidal-Puig, Antonio
Berge, Rolf K.
Lopez, Miguel
Steen, Vidar M.
Ferno, Johan
PSYCHOPHARMACOLOGY, 2012, 219 (03) : 783 - 794
[24] Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs
Stefanutti, Claudia
Julius, Ulrich
Watts, Gerald F.
Harada-Shiba, Mariko
Cossu, Maria
Schettler, Volker J.
De Silvestro, Giustina
Soran, Handrean
Van Lennep, Jeanine Roeters
Pisciotta, Livia
Kloer, Hans U.
Widhalm, Kurt
Moriarty, Patrick M.
JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (04) : 858 - 871
[25] Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, Evan A.
Raal, Frederick J.
CURRENT CARDIOLOGY REPORTS, 2015, 17 (11)
[26] Lipid-Lowering Agents Targets Beyond PCSK9
Hegele, Robert A.
Tsimikas, Sotirios
CIRCULATION RESEARCH, 2019, 124 (03) : 386 - 404
[27] Modern lipid-lowering drugs-A means to counter the problem of undertreatment?
Katzmann, Julius L.
Laufs, Ulrich
INNERE MEDIZIN, 2022, 63 (12): : 1316 - 1322
[28] Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuck, Larysa
Fogacci, Federica
Cicero, Arrigo Fg
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (07) : 611 - 621
[29] Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective
Jia, Xiaoming
Liu, Jing
Mehta, Anurag
Ballantyne, Christie M.
Virani, Salim S.
CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (06) : 1269 - 1279
[30] Lipid-lowering efficacy of atorvastatin
Adams, Stephen P.
Tsang, Michael
Wright, James M.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03):

← 1 2 3 4 5 →